Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB–IV NSCLC (LCDigital-IO Study): a multicenter retrospective study
Background The predictive efficacy of current biomarker of immune checkpoint inhibitors (ICIs) is not sufficient. This study investigated the causality between radiomic biomarkers and immunotherapy response status in patients with stage IB–IV non-small cell lung cancer (NSCLC), including its biologi...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | 文件 |
| 语言: | English |
| 出版: |
BMJ Publishing Group
2023-10-01
|
| 丛编: | Journal for ImmunoTherapy of Cancer |
| 在线阅读: | https://jitc.bmj.com/content/11/10/e007369.full |